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Abstract
Background: The kidneys ability to concentrate and dilute urine is deteriorated during progressive renal
insufficiency. We wanted to test the hypothesis that these phenomena could be attributed to an abnormal
function of the principal cells in the distal part of the nephron.
Methods: Healthy control subjects and patients with chronic kidney diseases were studied. Group 1 comprised
healthy subjects, n = 10. Groups 2-4 comprised patients with chronic kidney disease (Group 2, n = 14, e-GFR ≤ 90
m1/min; Group 3, n = 11, 60 m1/min ≤ e-GFR < 90 ml/min; and Group 4, n = 16, 15 ml/min ≤ e-GFR < 60 ml/
min). The subjects collected urine during 24 hours. A urine concentrating test was done by thirsting during the
following 12 hours. Thereafter, a urine diluting test was performed with a water load of 20 ml/kg body weight. The
effect variables were urinary excretions of aquaporin2 (u-AQP2), cyclic-AMP (u-c-AMP), urine volume (UV), free water
clearance (CH2O), urine osmolarity (u-Osm), and plasma arginine vasopressin (p-AVP).
Results: After fluid deprivation, u-Osm increased. In all groups, UV and CH2O decreased and u-AQP2 and u-c-AMP
increased in Groups 1 and 2, but were unchanged in Group 3 and 4. P-AVP was significantly higher in Group 4
than in the other groups. During urine diluting, UV and CH2O reached significantly higher levels in Groups 1-3 than
Group 4. Both before and after water loading, u-AQP2 and p-AVP were significantly higher and u-c-AMP was
significantly lower in Group 4 than the other groups. Estimated-GFR was correlated negatively to p-AVP and
positively to u-c-AMP.
Conclusions: Patients with moderately severe chronic kidney disease have a reduced renal concentrating and
diluting capacity compared to both patients with milder chronic kidney disease and healthy control subjects. These
phenomena can be attributed, at least partly, to an abnormally decreased response in the AVP-c-AMP-AQP2 axis.
ClinicalTrials.Gov Identifier: NCT00313430
Background
The capacity of the kidneys to concentrate and dilute
urine is an important mechanism to maintain constant
plasma osmolarity of the body fluid compartments.
Defects in both urine concentrating and diluting ability
have been measured in chronic kidney diseases, and in
diseases outside the kidneys associated with either fluid
retention as heart failure, liver cirrhosis and syndrome
of inappropriate antidiuretic hormone secretion or dehy-
dration as diabetes insipidus [1-3]. In addition, urine
diluting capacity is reduced in hypothyreoidism and
adrenal insufficiency with up regulation of AQP2 [4-6],
and urine concentration capacity is reduced in thyrotox-
icosis and glucocorticoid excess with down regulation of
AQP2 [7,8].
A normal concentrating and diluting capacity
demands delivery of fluid to the distal part of the
nephron, hypertonicity of renal medullar interstitial
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of the nephron. In addition, GFR and filtered load are
important factors in the process of urinary concentrat-
ing ability of the kidney, as they control the load deliv-
ered to the thick ascending limb, which generates and
maintains a hypertonic medullary interstitium. One or
more of these prerequisites might be abnormal during
the development and progression of chronic kidney dis-
ease. The consequence is an abnormal water transport
in the distal part of the nephron.
In the kidney, aquaporin-2 trafficking mediates water
transport across the apical cell membrane in principal
cells of the collecting ducts [2]. The short-term regula-
tion by vasopressin implies activation of V2 receptors
and subsequently trafficking of AQP-2 vesicles to the
apical plasma membrane resulting in increased water
permeability and absorption. The long-term regulation
is due to a change in AQP-2 mRNA expression fol-
lowed by AQP2 synthesis [2]. Mutation in the aqua-
porin2 gene causes nephrogenic diabetes insipidus.
Thus, an abnormal up- or downregulation of the aqua-
porin2 water channels in the principal cells seems to
be an important patophysiological factor in develop-
ment of concentrating and diluting defects in progres-
sive renal disesase [3,9-11]. However, it has never been
s t u d i e dt ow h a te x t e n tt h ef u n c t i o no ft h ep r i n c i p a l
cells is affected in patients with varying degrees of
reduced renal function, when evaluated by simulta-
neous measurements of urinary excretions of aqua-
porin2 (u-AQP2) and cyclic-AMP (u-c-AMP), and
plasma concentration of vasopressin (p-AVP) during
urine concentrating and diluting.
In the present study, we wanted to test the hypothesis
that u-AQP 2 and u-c-AMP were abnormal in chronic
kidney disease Stages I-IV [12], and that these variables
responded abnormal during urine concentrating and
dilution tests.
We performed urine concentrating test of 12 hours
duration, and urine diluting test of 5 hours duration in
healthy control subjects and patients with chronic kid-
ney diseases. The effect variables were u-AQP 2, u-c-
AMP, urine volume (UV), free water clearance (CH2O),
and p-AVP.
Methods
Participants
Healthy control subjects
Inclusion criteria: Both men and women; age 18- 65
years; body mass index < 30. Exclusion criteria: Clinical
signs or history of diseases in the heart, lungs, kidneys
or endocrine organs; abnormal laboratory tests (blood
hemoglobin, white cell count, platelet counts, plasma
concentrations of sodium,p o t a s s i u m ,c r e a t i n i n e ,
albumine, bilirubine, alanine-aminotransferase, and
cholesterol; blood glucose; and albumin and glucose in
urine); malignancies; arterial hypertension (i.e. casual
blood pressure > 140/90 mmHg); alcohol abuse (more
than 21 drinks per week for males and more than 14 for
females); medical treatment; pregnancy; breast-feeding;
lack of oral contraceptive treatment to women in the
fertile age; intercurrent diseases; medicine abuse; dona-
tion of blood less than 1 month before the study; and
unwillingness to participate. Withdrawal criteria: Devel-
opment of one or more of the exclusion criteria, and
problems with blood sampling or urine collection.
Patients
Inclusion criteria: Both men and women; age 18- 75
years; a diagnosis of hypertension or an estimated GFR
(e-GFR) between 15-90 ml/min. Exclusion criteria: heart
failure; heart arrhythmias; pulmonary insufficiency; liver
disease with plasma alanine aminotransferase >100 U/L;
previous cerebrovascular insult; diabetes mellitus; other
endocrine diseases than diabetes mellitus not satisfacto-
rily controlled; malignancies; alcohol abuse (more than
21 drinks per week for males and more than 14 for
females); abuse of medicine; pregnancy; other diseases
or conditions prohibiting participation in the trial;
unwillingness to participate. Withdrawal criteria: Devel-
opment of one or more of the exclusion criteria, and
problems with blood sampling or urine collection.
Design
The investigation was as a case-control study.
Ethics
The local Medical Ethics Committee approved the study
(j. no. 2580-04). All participants received written infor-
mation and gave their consent by signature. The study
was carried out in compliance with the Helsinki
Declaration.
Recruitment
Healthy participants were recruited by advertisements in
public and private institutions in Holstebro. Patients
with primary hypertension or chronic renal failure were
recruited from the Out-patients’ Clinic, Department of
Medicine, Section of Nephrology, Holstebro Hospital.
Experimental procedure
An ambulatory 24 hours blood pressure was made
before the participants began the study procedure.
The study started 36 hours before the participants
arrived in the laboratory. Part 1(Control period): Urine
was collected during 24 hours from 07.30 p.m.-07.30
p.m. The subjects maintained their normal daily activ-
ities, ate their usual diet, and had usual fluid intake.
They followed their normal medical prescriptions. Part
2: (Urine concentrating test): From 07.30 p.m., the night
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next day, a 12 hours urine collection was done, followed
by one hour urine collection from 07.30 to 08.30, while
the participants fasted and thirsted. Part 3 (Urine dilu-
tion test): Urine was collected in the following 6 periods:
08.30-09. 30 a. m.; 09.30-10. 30 a. m.; 10.30-11.30 a. m.;
11.30 a.m. -00.30 p. m.; 00.30-01.30 p.m.; 01.30-02.30 p.
m. An oral water load (tap water, 20 ml per body kg
weight) was given from 9.30- 9.45 a.m.
The participants arrived at 7.30 a.m. in the laboratory.
An intravenous catheter was inserted in a vein in fossa
cubiti in one arm for collecting blood samples every
hour. The participants were in the supine position
except during voiding, which took place in the sitting or
standing position. A light meal consisting of one slice of
toast with jam was served at 08.30 a.m. All morning
medication was postponed to the end of the study.
Blood samples were drawn for measurements of p-
AVP, p-Osm, p-creatinine every hour, starting at 08.30
a.m. In addition, blood samples were drawn for determi-
nation of b-hemoglobin, p-sodium, p-potassium, p-albu-
min, p-glucose, p-ALAT, and for women a pregnancy
test, at 08.30 a.m.
Urine samples were analyzed for u-AQP2, u-Osm, u-
creatinine, and u-c-AMP. Blood pressure and pulse rate
were measured once every hour during the examination.
Effect variables
The main effect variable was u-AQP2, and other effect
variables were u-Osm, p-AVP, and u-c-AMP, UV and
CH2O.
Number of subjects
Using a significance level of 5% and a power of 90%, it
could be calculated that the number of subjects in each
group should 10-15, when the minimal relevant differ-
ence in u- AQP2 was 0.3 ng/min and SD was 0.2 ng/
min.
Measurements
U-AQP-2 was measured by radioimmunoassay as pre-
viously described, and antibodies were raised in rabbits
to a synthetic peptide corresponding to the 15 COOH-
terminal amino acids in human AQP2 to which was
added an NH2-terminal cystein for conjugation and affi-
nity purification [13]. Minimal detection level was 32
pg/tube. The coefficients of variation were 11.7% (inter-
assay) and 5.9% (intra-assay).
U-c-AMP w a sm e a s u r e du s i n gak i to b t a i n e df r o mR
&DS y s t e m s ,M i n n e a p o l i s , MN, USA. Minimal detec-
tion level was 12.5 pmol/tube. The coefficients of varia-
tion were 6.9% (inter-assay) and 5.3% (intra-assay).
Blood samples for determination of p-AVP were cen-
trifuged for 15 minutes at 3000 rpm at 4°C. Plasma was
s e p a r a t e df r o mb l o o dc e l l sa n dk e p tf r o z e na t- 2 0 ° C
until assayed. AVP was extracted from plasma with C18
Sep-Pak (Water associates, Milford, MA, USA), and sub-
sequently determined by radioimmunoassay [14]. The
antibody against AVP was a gift from Professor Jacques
Dürr, Miami, FL., USA. Minimal detection level was 0.5
pmol/L. The coefficients of variation were 13% (inter-
assay) and 9% (intra-assay).
Plasma and urinary osmolality were measured by
freezing-point depression (Advanced Model 3900 multi-
sampling osmometer).
Blood pressure was measured with UA-743 digital
blood pressure meter (A&D Company, Tokyo, Japan)
P l a s m aa n du r i n a r yc o n c e n t r a t i o n so fcreatinine was
measured by routine methods at the Department of
Clinical Biochemistry, Holstebro Hospital, Denmark.
The estimated glomerular filtration rate (e-GFR) was
calculated according to the following formulas [15]:
Men: e-GFR (ml/min/70 kg)
88 (145- age in years)/p-creatin =× i in (mikromol/l)-3
Women: e-GFR (ml/min/70 kg)
75 (145- age =×    in years)/p-creatinin (mikromol/l)-3
Free water clearance was calculated according to the
formula CH2O =UV*u-Osm/p-Osm, where CH2O is free
water clearance in ml/min, UV is urine volume in ml/
min, u-Osm is urine osmolarity mosmol/l, and p-Osm is
plasma osmolarity in mosmol/l.
Statistics
Statistical level of significance was P < 0.05 in all ana-
lyses. Kruskal-Wallis’st e s ta n dF r i e d m a n ’st e s t sw e r e
used to analyze differences between several unpaired
a n dp a i r e dg r o u p s ,r e s p e c t i v e l y .M a n n - W h i t n e y ’st e s t
and Wilcoxon’s signed rank test were used to analyze
differences between two unpaired and paired groups,
respectively. For the urine diluting test, we used A Gen-
eral Linear Model with Repeated Measures for compari-
son between and within groups. Spearman’sr h ot e s to r
Pearson’s test were used for analysis of correlations
between to variables. Multiple regression analysis was
used to measure the influence of several effect variables
on the amount of water excreted during urine diluting
test. Values are given as medians with interquartile
ranges in brackets, or as median with 25 and 75 quar-
tiles. SPSS version 11.5 was used for the statistical
analyses.
Results
Demographics
Healthy control subjects
Sixteen healthy subjects were recruited. Six subjects
were excluded, five due to abnormal 24 hours
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incorrect urine collection. Thus, ten subjects fulfilled the
study (Group 1), five women and five men, with a med-
ian age of 41 years (range 30-54 years), a median body
mass index of 23 (range 20-27) and a median e-GFR of
108 ml/min/kg (range 93-142 ml/min/kg).
Patients
Forty-one patients were included and fulfilled the study.
The patients were classified in three groups according
to e-GFR (Groups 2-4). Group 2 (n = 14) comprised 6
women and 8 men, with a median age of 49 years
(range 30-58 years), a median body mass index of 26
(range 20-35) and a median e-GFR of 99 ml/min/70 kg
(range 90-140 ml/min/70 kg). Group 3 (n = 11) com-
prised 1 woman and 10 men with a median age of 53
years (range 39-71 years), a median body mass index of
26 (range 23-34) and a median e-GFR of 79 ml/min/70
kg (range 65-89 ml/min/70 kg). Group 4 (n = 16) com-
prised 4 women and 12 men with a median age of 59
years (range 37-73 years), a median body mass index of
27 (range 22-32) and a median e-GFR of 25 ml/min/70
kg (range 12-56 ml/min/70 kg).
The primary renal disease was nephrosclerosis (n =
11), chronic glomerulonephritis (n = 7), adult polycystic
kidney disease (n = 3), interstitial nephropathy (n = 1),
and unknown nephropathy (n = 19). All patients
received antihypertensive treatment in various combina-
tions, i.e.loop diuretics (n = 11), calcium channel
antagonists (n = 14), thiazides (n = 15), angiotensin con-
verting enzyme inhibitors (n = 16), angiotensin II recep-
tor antagonists (n = 16), b-adrenergic blockers (n = 16),
a-adrenergic blockers (n = 3), and a-calcidol (n = 4).
We did not see any deterioration in renal function
either during urine concentrating or diluting test.
Urine concentration test
Table 1 shows u-Osm, UV, CH2O, u-c-AMP and u-
AQP2 during the urine concentrating test.
In all groups U-Osm increased during a 12 hours per-
iod of thirsting. The increase in u-Osm was significantly
lower in Group 4 than in Group 1, and the increase was
especially reduced in patients with decreased renal func-
tion (Group 1: 47%, Group 2: 65%, Group 3: 14%, and
Group 4: 10%).
Urine volume decreased significantly in Groups 1 and 2
(Group 1: -49%, Group 2:- 49%), when comparison was
made between the levels during 24 hours and during one
hour after the 12 hours thirsting period. In addition, a
tendency to decrease in UV was measured during the 12
hours thirsting period. Contrarily, in Groups 3 and 4, UV
tended to increase during the 12 hours of thirsting, and
at the end of the concentrating test, UV was not signifi-
cantly changed in Group 3 (-15%), and was only border-
line significantly reduced in Group 4 (-29%).
Free water clearances fell significantly in Group 1
(-17%) and in Group 2 (-40%), whereas the levels were
approximately unchanged in Group 3 (-5%) and Group
4 (-7%), when comparison was made between the levels
during 24 hours and during one hour after the 12 hours
thirsting period.
The concentration of c-AMP was approximately at the
same level in Groups 1-3 during 24 hours urine collection.
U-c-AMP increased significantly in Group 1 (91%) and
Group 2 (138%), when comparison was made between the
levels during 24 hours and during one hour after the 12
hours thirsting period. There was no significant increase
in u-c-AMP in groups 3 and 4, although a tendency to
increase in u-c-AMP was measured in Group 3 (55%).
The concentration of AQP2 in urine increased signifi-
cantly in Group 1 and 2 during the urine concentrating
test. In Group 3 and 4, u-AQP2 was no significantly
changed during water deprivation.
P-AVP was the same in Groups 1 to 3 (Group 1: 0.95
pmol/l (0.33), median with interquartile range, Group 2:
0.75 pmol/l (0.55), and Group 3: 1.00 pmol/l (0.83), NS).
The level in Group 4 was significantly higher than in
the other three groups (Group 4: 1.80 pmol/l (1.68), p <
0.000).
Urine diluting test
Table 2 shows UV, CH2O,u - o s m ,u - c - A M P ,a n du -
AQP2 during the urine diluting test.
The amount of water given was in Group 1:1389 ml
(371), in Group 2: 1581 (416), in Group 3: 1674 ml
(416), and in Group 4: 1572 ml (374). The amount of
water excreted during the first four hours after water
loading was significantly lower in Group 4 than in the
other three Groups (Group 1: 1376 ml/4 hours (465),
median with interquartile range, 100% (44) of the water
load, Group 2: 1210 ml/4 hours (662), 81% (30) of the
water load, Group 3: 1536 ml/4 hours (524), 93% (32) of
the water load, and Group 4: 797 ml/4 hours (363), 53%
(17) of the water load).
Both UV and CH2O increased in all groups during the
diluting test. UV and CH2O reached a significantly
higher level during urine diluting in Groups 1, 2, and 3
c o m p a r e dw i t hG r o u p4 ,i .e .U V( G r o u p1 :1 2f o l d ,
Group 2: 9 fold, Group 3: 9 fold, and Group 4: 2 fold),
and CH2O (Group 1: 9.0 ml/min, Group 2: 6.5 ml/min,
Group 3: 9.8 ml/min, and Group 4: 1.9 ml/min). U-osm
decreased significantly in all groups. In Group 4, u-osm
was significantly higher than in the other groups during
the second and third hour of the test.
U-c-AMP was unchanged during urine diluting test in
all four groups. However, u-c-AMP was significantly
lower in Group 4 than in the other three groups.
U-AQP2 decreased during urine diluting test in all
groups. The statistical analyses showed that the level of
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other three groups during the different periods of the
test. U-AQP2 was the same during the test in Groups 1,
2, and 3. The maximum decrease did not deviate signifi-
cantly between the groups, u-AQP2 (Group 1: - 27%,
Group 2: - 33%, Group 3: - 32%, and Group 4: - 19%).
Table 3 shows that p-AVP was significantly reduced in
all four groups during urine diluting test. The maximum
reduction was most pronounced in Group 1 (Group 1: -
4 0 % ,G r o u p2 :-1 1 % ,G r o u p3 :-1 4 % ,a n dG r o u p4 :-
27%). The level of p-AVP was significantly higher in
Group 4 than in the other three groups, in which
p-AVP was approximately in the same level. P-osm
decreased significantly in all groups and was normalized
in the last period of the test in Groups 1 and 2.
Blood pressure
Twenty-four hours BP was significantly different
between the groups (Group 1: 123/74 (16/9.8) mm Hg,
median and interquartile range, Group 2: 130/81 (12/
7.0) mm Hg, Group 3:129/79 (13/8.0) mm Hg, Group 4:
140/83 (18/10) mm Hg) for both systolic and diastolic
BP (0.004/0.005, Kruskal-Wallis test). The statistical
analyses showed that the level in Group 4 was
Table 1 Urine concentrating test
24 hours urine collection without fluid
deprivation (19.30 to 19.30)
12 hours urine collection with fluid
deprivation (19.30 to 07.30)
One urine collection fluid
deprivation (07.30-08.30)
U-osm (mosmol/l)
Group 1 561(357) 473(344) 823(213) *
Group 2 405(286) 369(460) 670(193) *
Group 3 472(303) 411(96) 547(223) *
Group 4 359(119) 351(126) 396(153) *
P (Kruskal-Wallis) 0.169 0.188 0.000
UV (ml/min)
Group 1 1.40(1.15) 1.08(1.02) 0.72(0.42) *
Group 2 1.91(1.26) 1.42(1.50) 0.97(0.94) *
Group 3 1.38(0.67) 1.69(0.41) 1.17(1.04)
Group 4 1.77(1.00) 1.84(0.67) 1.25(0.89) *
P (Kruskal-Wallis) 0.156 0.043 0.006
CH20 (ml/min)
Group 1 -0,94(1.35) -0,38(0.44) -1.10(0.55)*
Group 2 -0,64(1.35) -0,45(1.50) -0,90(0.57) *
Group 3 -1.29(1.29) -0,71(0.80) -1,22(0.82)
Group 4 -0,28(0.84) -0,13(0.73) -0,30(0.66)
P (Kruskal-Wallis) 0.095 0.149 0.03
U-c-AMP (pmol/l)
Group 1 2.53(1.53) 3.00(2.27) 4.83(4.82)*
Group 2 2.01(0.96) 2.83(2.87) 4.79(4.67) *
Group 3 2.36(0.66) 1.96(0.95) 3.65(2.45)
Group 4 1.20(1.37) 1.31(1.02) 1.20(1.17)
P (Kruskal-Wallis) 0.000 0.000 0.000
U-AQP2 (ng/ml)
Group 1 0.68(0.88) 0.96(1.63) 0.72(1.26) *
Group 2 0.54(0.44) 0.51(0.98) 0.73(0.52) *
Group 3 1.13(0.47) 0.69(0.49) 0.87(0.33)
Group 4 0.79(0.63) 0.71(0.66) 0.63(0.61)
P (Kruskal-Wallis) 0.048 0.793 0.423
Urinary osmolarity (u-osm), urine volume (UV), free water clearance (CH2O), urinary excretions of cyclic-AMP (u-c-AMP) and aquaporin2 (u-AQP2) in a 24 hours
urine collection with unrestricted fluid intake, in an immediately following 12 hours urine collection with fluid deprivation (19.30 to 07.30), and in an immediately
following one hour urine collection with fluid deprivation (07.30-08.30).
Group 1 comprised healthy control subjects (n = 10). Groups 2-4 comprised patients with chronic kidney disease or hypertension (Group 2 (n = 14), e-GFR ≥ 90
ml/min; Group 3 (n = 11), 60 ml/min ≤ e-GFR < 90 ml/min; and Group 4 (n = 16), 15 ml/min < e-GFR ≤ 60 ml/min).
Median with Interquartile Range in brackets. Kruskal-Wallis’s test was used to analyze differences between groups during the concentration test. Wilcoxon’s
signed rank test was used to analyze differences in variables between baseline (24 hours urine) and the end of the test (one hours urine), * = P < 0.05.
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during 24 hours was the same in the groups (Group 1:
70 (13) beats/min, median and interquartile range,
Group 2: 70 (12) beats/min, Group 3: 65 (15) beats/min,
and Group 4: 69 (10) beats/min.
During the experimental procedure BP was measured
seven times. The initial level was in Group 1: 107/62
(14/13) mm Hg, Group 2: 117/78 (24/15) mm Hg,
Group 3: 123/74 (22/19) mm Hg, and Group 4: 126/77
(25/13) mm Hg. The BP and pulse levels did not deviate
Table 2 Urine volume (UV), free water clearance (CH20), urine osmolarity (u-osm), urinary excretions of cyclic AMP (u-c-
AMP) and aquaporin2 (AQP2) during urine diluting test
Baseline Post
0-60
Post
60-120
Post
120-180
Post
180-240
Post
240-300
P
(GLM-within)
UV (ml/min)
Group 1 0.8(0.4) 2.4(3.0) * 10.7(6.3)* 7.4(4.2) * 2.1(4,1) * 1.2(1.5)
0.000 Group 2 0.8(0.8) 1.9(2.8) * 7.2(5.7) * 8.2(3.1) * 3.5(2.2) * 1.3(1.8) *
Group 3 1.1(1.0) 3.0(1.8) * 11.7(8.0)* 8.0(8.3) * 3.8(4.8) * 1.4(0.8)
Group 4 1.3(0.9) 2.0(1.4) * 3.7(1.6) * 4.1(2.8) * 2.7(0.9) * 2.2(1.6) *
P (GLM-between) 0.002
P (Kruskal-Wallis) 0.016 0.869 0.000 0.001 0.246 0.016
CH20 (ml/min)
Group 1 -1.1(0.5) -0.1(3.0) * 7.9(5.5) * 5.0(3.9) * -0,43(4.0) * -0.8(1.4)
0.000 Group 2 -0.9(0.6) -0,4(2.5) 4.4(5.7) * 5.6(2.8) * 1.5(3.0) * -0.3(1.9) *
Group 3 -1.1(1.0) -0.9(1.5) 8.7(8.4) * 5.4(8.2) * 1.3(4.3) * -0.8(1.0) *
Group 4 -0.3(0.6) -0.4(0.5) 1.6(0.9) * 1.5(2.6) * 0.9(1.4) * 0.1(0.8) *
P (GLM-between) 0.000
P (Kruskal-Wallis) 0.003 0.264 0.000 0.001 0.309 0.017
U-osm (mosmol/l)
Group 1 709(258) 271(360)* 72(46)* 98(80)* 394(334)* 637(388)*
0.000 Group 2 678(175) 372(386)* 104(68)* 95(33)* 146(186)* 355(403)*
Group 3 555(247) 448(285)* 86(148)* 92(122)* 219(265)* 452(216)*
Group 4 397(145) 352(101)* 190(63)* 166(116)* 203(129)* 262(90)*
P (GLM-between) 0.000
P (Kruskal-Wallis) 0.000 0.484 0.000 0.001 0.100 0.027
U-c-AMP (μg/min)
Group 1 3.07(1.35) 3.83(1.77) 3.48(1.31) 3.07(1.28) 3.24(0.94) 2.97(1.48)
0.254 Group 2 3.88(2.45) 4.21(2.52) 3.91(1.56) 3.96(2.17) 3.41(3.24) 3.55(1.04)
Group 3 3.20(1.04) 3.84(1.58)* 4.43(2.33) 3.82(2.88) 3.34(2.31) 3.00(1.31)
Group 4 1.74(1.18) 1.99(1.34) 1.20(2.02) 1.20(1.24) 1.91(0.85) 2.50(1.33)
P (GLM-between) 0.000
P (Kruskal-Wallis) 0.000 0.000 0.001 0.000 0.000 0.001
U-AQP2 (ng/min)
Group 1 1.01(0.20) 1.05(0.19) 0.91(0.51) 0.78(0.27)* 0.74(0.33) * 0.74(0.33) *
0.321 Group 2 0.97(0.52) 1.04(0.63) 0.85(0.55) 0.91(0.31) 0.69(0.34) * 0.65(0.21) *
Group 3 1.16(0.88) 1.42(0.86) 1.31(1.14) 1.16(0.67) 0.99(0.28) 0.79(0.47) *
Group 4 1.28(0.78) 1.74(0.82) 1.40(0.52) 1.14(0.49)* 1.03(0.56) * 1.21(0.58)
P (GLM-between) 0.002
P (Kruskal-Wallis) 0.157 0.036 0.063 0.022 0.000 0.000
Baseline was mean of two 60 minutes control periods before water loading. An oral water load of 20 ml/kg body weight was given during the first 15 minutes of
the following 60 minute’s period (Post 0-60). Urine was subsequently collected during four consecutive 60 minute’s periods (Post 60-120, Post 120-180, Post 180-
240, and Post 240-300. Group 1 comprised healthy control subjects (n = 10). Groups 2-4 comprised patients with chronic kidney disease or hypertension (Group
2 (n = 14), e-GFR ≥ 90 ml/min; Group 3 (n = 11), 60 ml/min ≤ e-GFR < 90 ml/min; and Group 4 (n = 16), 15 ml/min < e-GFR ≤ 60 ml/min).
Median with Interquartile Range in brackets. A General Linear Model (GLM) for Repeated Measures was used for comparison within and between groups. Kruskal-
Wallis’s test was used to analyze differences between groups during the diluting test. Wilcoxon’s signed rank test was used in each group to analyze significant
deviations from baseline (* = P < 0.05).
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Page 6 of 10significantly from baseline level during the urine diluting
test (Data not shown).
Relationship between e-GFR and AVP, c-AMP and AQP2
Correlation analyses were performed for the whole study
population on data from baseline before the urine dilut-
ing test. E-GFR was significantly correlated with p-AVP
(r = - 0.618, P < 0.000), u-c-AMP (r = 0.536, P <
0.000), and u-AQP2 (r = - 0.288, P < 0.05). The influ-
ence of e-GFR on effect variables were measured using
am u l t i p l er e g r e s s i o na n a l y s i s( T a b l e4 ) .T h ed e p e n d e n t
variable was the amount of water excreted during the
first four hours after water loading in percent of the
given water load during the urine diluting test (20 ml/
kg/body weight). The independent variables were p-
AVP, u-c-AMP, AQP2, 24 hours systolic and diastolic
blood pressure, and e-GFR. The analysis showed that
the partial regression coefficient was significant for
e-GFR, but not for the other effect variables in the
analysis.
Discussion
Our study showed that patients with a renal function
corresponding to chronic kidney disease stage III and
I V ,i .e .1 5≤ e-GFR < 60 ml/min, have a reduced renal
concentrating and diluting capacity compared to both
patients with milder chronic kidney disease or hyperten-
sion, corresponding to stage I and II, i. e. GFR ≥ 60 ml/
Table 3 Plasma concentration of vasopressin (p-AVP) and plasma osmolaririty (p-osm) during urine diluting test
Baseline Post
0-60
Post
60-120
Post
120-180
Post
180-240
Post
240-300
P
(GLM-within)
AVP (pmol/l)
Group 1 1.00(0.40) 0.7(0.10) * 0.60(0.25)* 0.70(0.35)* 0.90(0.65) 1.00(0.45)
0.000 Group 2 0.75(0.45) 0.60(0.08)* 0.60(0.18)* 0.60(0.10)* 0.70(0.60) 0.80(0.45)
Group 3 0.70(0.53) 0.60(0.08)* 0.60(0.15)* 0.60(0.15)* 0.65(0.63) 0.80(0.60)
Group 4 1.80(1.85) 1.10(0.83)* 1.10(0.88)* 1.30(0.93)* 1.50(0.85)* 1.65(1.25)*
P (GLM-between) 0.000
P (Kruskal-Wallis) 0.000 0.000 0.000 0.000 0.001 0.002
P-osm (mosmol/l)
Group 1 290(6) 283(3) * 284(6)* 287(5)* 286(5)* 287(4)
0.000 Group 2 288(7) 283(8)* 284(8)* 286(9)* 286(9)* 288(8)
Group 3 291(11) 285(7)* 287(9)* 289(6)* 288(4)* 289(6)*
Group 4 305(14) 299(15)* 298(14)* 297(14)* 297(14)* 299(13)*
P (GLM-between) 0.000
P (Kruskal-Wallis) 0.000 0.000 0.000 0.000 0.000 0.000
Blood samples were drawn after a baseline period of 120 minutes, and after the end of five consecutive periods each of one hour duration (Post 0-60, Post 60-
120, Post 120-180, Post 180-240, and Post 240-300. An oral water load of 20 ml/kg body weight was given during the first 15 minutes of the Post 0-60 period.
Group 1 comprised healthy control subjects (n = 10). Groups 2-4 comprised patients with chronic kidney disease or hyperension (Group 2 (n = 14), e-GFR ≥ 90
ml/min; Group 3 (n = 11), 60 ml/min ≤ e-GFR < 90 ml/min; and Group 4 (n = 16), 15 ml/min < e-GFR ≤ 60 ml/min).
Median with Interquartile Range in brackets. A General Linear Model (GLM) for Repeated Measures was used for comparison within and between groups. Kruskal-
Wallis’s test was used to analyze differences between groups during the diluting test. Wilcoxon’s signed rank test was used in each group to analyze significant
deviations from baseline (* = P < 0.05).
Table 4 Multiple regression analysis with excreted water as dependent variable during urine diluting test
Independent variables B SE b tP
P-AVP (pmol/l) 5.184 5.844 0.154 0.887 0.381
U-c-AMP (pmol/l) -0.002 0.003 -0.93 -0.586 0.562
U-AQP2 (ng/ml) -13.270 8.415 -0.242 -1.577 0.123
SBP (mm Hg) 0.035 0.472 0.015 0.075 0.940
DBP (mm Hg) -0.366 0.721 -0.105 -0.507 0.615
E-GFR (ml/min) 0.487 0.159 0.613 3.066 0.004
The amount of water excreted during the first four hours after water loading in percent of the given water load during the urine diluting test (20 ml/kg/body
weight) as dependent variable and plasma concentration of vasopressin (p-AVP), urinary excretions of cyclic AMP (u-c-AMP) and aquaporin2 (AQP2), 24 hours
systolic and diastolic blood pressure (SBP and DBP), and estimated GFR (e-GFR) as independent variables in a multiple regression analysis at the start of the urine
diluting test in the whole study population (n = 41) comprising healthy control subjects (n = 10) and patients with chronic kidney disease or hypertension (n =
31; Group 2 (n = 14), e-GFR ≥ 90 ml/min; Group 3 (n = 11), 60 ml/min ≤ e-GFR < 90 ml/min; and Group 4 (n = 16), 15 ml/min < e-GFR ≤ 60 ml/min).
Unstandardized partial regression coefficients (Β), standard error (SE), standardized partial regression coefficient (β), t- value (t), and significance (P).
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Page 7 of 10min, and healthy control subjects. Our analyses showed
that these phenomena can be attributed, at least partly,
to an abnormal function of the AVP-c-AMP-AQP2 axis.
In healthy subjects, AVP stimulates vasopressin recep-
tors on the principal cells in the collecting ducts of
nephron. This results in an increased production of c-
AMP, which through a cascade of intracellular reactions
upregulate the AQP 2 water channels, and thereby pro-
motes water transport from the tubular lumen to the
cell. Subsequently, water is further transported to the
interstitial fluid through aquaporin 3 and 4 water chan-
nels [2]. In previous studies, we have demonstrated that
u-AQP2 reflects the functional status of the aquaporin2
water channels during urine concentrating and diluting
procedures [13,16,17]. Urinary excretion of u-c-AMP is
a measure of the renal production of c-AMP. Thus, the
function of the principal cells can be determined by
measurements of u-AQP2 and u-c-AMP together with
p-AVP.
The renal concentrating ability is a defense mechan-
ism to prevent water depletion and hyperosmolarity in
body fluids. A decrease in urinary concentrating ability
can have several reasons. Firstly, the delivery of tubular
fluid can be diminished due to a fall in GFR. Secondly,
the ability to generate interstitial hypertonicity can be
r e d u c e dd u et od e c r e a s e ds o d i u ma n dc h l o r i d ea b s o r p -
tion in the ascending limb of Henle, decreased urea
accumulation, or a change in renal medullar blood flow.
Thirdly, the response to vasopressin may be reduced or
absent [18,19].
After the urine concentrating test, we measured a sig-
nificant increase in u-Osm in all groups, and UV and
CH2O were clearly and significantly reduced in Groups 1
and 2. However, in Groups 3 and 4 CH2O was
unchanged, and UV was unchanged or only borderline
changed in Groups 3 and 4, respectively. Thus, the
increase in u-Osm and the fall in UV and CH2O were
smaller in patients with reduced renal function, which
indicated a reduced concentrating ability. Our study also
showed that u-c-AMP was decreased in patients with an
e-GFR < 60 ml/min, and the correlation analyses
showed a significantly, positive correlation between e-
GFR and u-c-AMP. Thus, the kidneys’ ability to synthe-
size c-AMP decreased with deteriorating renal function.
This phenomenon might be attributed to a reduced sen-
sitivity to AVP, because p-AVP was increased in patients
with e-GFR < 60 ml/min and correlated inversely with
e-GFR in the whole group of study subjects. The con-
centration of AQP2 was not significantly changed dur-
ing the urine concentrating test in Groups 3 and 4, but
increased significantly in the other two groups. This is
in good agreement with the lack of increase in u-c-AMP
in Groups 3 and 4. Thus, our study showed that the
reduced renal concentrating capacity during decreasing
renal function can be attributed, at least partly, to a lack
of responsiveness to vasopressin of the principal cells in
the distal tubules. Our results are in agreement with a
previous small study of patients with diabetic nephropa-
thy, in whom a decrease in u-AQP2 was associated with
impaired urinary concentrating ability [20]. In addition,
our results are in good accordance with animal experi-
ments, which have demonstrated a vasopressin resistant
down regulation in expression of AQP2, when urinary
concentrating ability was impaired, i. e. in nephrogenic
diabetes insipidus, post-obstructive polyuria, and renal
failure [1-3,9].
The renal diluting mechanism is a defense mechanism
against water intoxication and hypoosmolarity.. An
abnormal diluting capacity can be attributed to several
factors. Firstly, a decrease of tubular fluid to the diluting
segments of the nephron can be caused by a diminished
GFR, an increased absorption of sodium and water in
the proximal tubules or both. Secondly, an abnormally
reduced absorption of sodium and chloride in the thick
ascending limb of Henle or in the distal convoluted
tubule can prevent establishment of sufficient interstitial
hypertonicity.
Thirdly, plasma level of vasopressin may be increased
due to drug treatment or primary diseases outside the
kidneys as heart failure, liver cirrhosis with fluid reten-
tion, hypothyroidism and adrenal insufficiency [3].
Treatment with a vasopressin receptor antagonist
reversed the consequence of non-osmotic increase in
vasopressin release in these conditions and improved
urinary dilution, and animal studies showed that AQP2
expression was increased [4-6].
Our study showed that urine diluting capacity was
decreased in patients with moderately reduced renal func-
tion. Thus, the amount of excreted water represented
more than 80% of the load during the first four hours after
the load was given in Groups 1, 2 and 3, but only half of
the load was excreted in Group 4. This corresponded very
well with the increase in both UV and CH2O in all groups
and a much lower increase in Group 4 than the other
three groups. During urine dilution, p-AVP was reduced
in all groups, but the level was significantly higher in
patients with e-GFR < 60 ml/min, and p-AVP correlated
significantly and inversely with e-GFR during all periods of
the test. In addition, u-c-AMP was lower in Group 4 than
in Groups 1, 2 and 3 and correlated significantly and posi-
tively with e-GFR during the whole test. Thus, our results
showed that the high level of p-AVP in Group 4 failed to
control c-AMP, presumably due to a defect function of
the principal cells induced by the chronic kidney disease.
This leaves the function of the AQP2 water channels with-
out regulatory influence of the AVP-c-AMP-axis. U-AQP2
was reduced during urine dilution in all groups, but the
level was higher in Group 4 that in the other three groups
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ciency in regulatory influence on the formation of AQP2
water channels by the AVP-u-c-AMP-axis. Our results
suggest that the abnormal urine dilution capacity in
chronic kidney disease stage III and IV is due to a lower
ability of the principal cell in the distal part of the nephron
to down regulate the expression of the AQP2 water chan-
nels and in that way promote water excretion. However, it
is likely that the reduced GFR and a reduced hypertonicity
in the renal interstitial tissue contributed to the reduced
urine diluting capacity in chronic kidney disease.
Among several variables, the multiple regression ana-
lysis demonstrated that e-GFR was the most important
factor to determine the extent of disturbance in the
AVP-AMP-AQP2-axis, and thus the degree of deteriora-
tion in urine concentrating and diluting ability in
chronic kidney disease.
We have used established procedures to test urinary
concentrating and diluting capacity [21]. Several differ-
ent formulas have been suggested for estimation of GFR
using p-creatinine, gender, body weight, height and eth-
nicity in various combinations [22]. Each of these esti-
mates of GFR has weaknesses and strengths. In the
present study, we have chosen the Hull-equation to esti-
mate GFR [15]. We have also calculated e-GFR accord-
ing to the MDRD-equations [23-25]. Using correlation
analyses, we found a highly significant correlation
between e-GFR estimated by the Hull-equation and
both the original MDRD equation from 1999 (r = 0.978,
n = 51, P < 0.000) and the new MDRD equation from
2009 (r = 0.985, n = 51, P < 0.000). Thus, it is unlikely
that small differences in e-GFR from different formula
would have changed the conclusions of our study, even
if we had used either older or newer equations [23-25].
Urine concentrating ability is decreased in the aging
mammalian kidney [26]. A functional impairment of
renal concentrating ability was demonstrated in aged
rats [27]. This phenomenon appeared to be related to
decreased responsiveness of the kidney to vasopressin
caused by a down regulation of the renal vasopressin 2
receptor and AQP2 abundance [27]. We measured a
marked difference in urine concentrating and diluting
ability between the three groups of patients in the pre-
sent study, in spite of a rather narrow age range
between the groups with medians between 49 and 59
years. Thus, it is unlikely that differences in age between
the three groups of patients could explain our findings.
We studied different types of renal diseases. During
progressive deterioration in renal function urinary con-
centrating and diluting ability may be affected differently
depending on the nature of the disease, i.e. in primarily
glomerular, tubular, interstitial or vascular pathogenesis.
However, we demonstrated clear abnormalities in urine
concentrating and diluting ability during progression to
Stage III and IV despite differences in etiology of the
disease.
A large proportion of the patients in the present study
received antihypertensive treatment, which might influ-
ence the activity in the renin-angiotensin-aldosterone
system, natriuretic peptide system, and sympathetic ner-
vous activity. In addition to vasopressin, these homeo-
static systems have a modulating influence on the
transport in the aquaporin2 water channels [28-32]. It
would have been ideal to perform studies after withdra-
wal of all antihypertensive treatment. This was not
done, since we did not find it ethically justified to dis-
continue antihypertensive therapy. The prostaglandin
system can also modulate the transport via aquaporin2
water channels, but none of the patients in the present
study received non-steroid-anti-inflammatory drugs.
The present study comprised three patients with poly-
cystic kidney disease. Animal studies indicated that
vasopressin regulates cystogenesis [33], which has been
basis for ongoing clinical trials regarding the effect of
vasopressin antagonists on cyst growth and deterioration
o fr e n a lf u n c t i o ni np a t i e n t sw i t hP K D[ 3 4 ] .O t h e r
ongoing trials study the effect of statins, blockade of the
renin-angiotensin system, sirolimus, and somatostatins
in PKD [35]. At the time being, it is far from clarified,
whether these therapeutic aspects will be effective
regarding cyst growth and preservation of renal function
in patients with PKD or have influence on the abnormal
urine concentrating and diluting ability in progressive
renal disease. Neither is it known whether polycystic
kidney per se will change urine concentrating and dilut-
ing ability. However, we have analyzed our data with
exclusion of the three patients with PKD, and the results
and conclusions were unchanged.
Conclusions
The function of AVP-c-AMP-AQP2 axis was abnormal
in patients with an e-GFR between 15 and 60 ml/min.
The ability to concentrate urine was decreased in renal
insufficiency due to an impaired and reduced response
in c-AMP and AQP2 to AVP, which was elevated in
plasma, presumably as a compensatory phenomenon.
T h ea b i l i t yt od i l u t eu r i n ew a sd e t e r i o r a t e di nr e n a l
insufficiency, presumably due to both a lack of suppres-
sion in AVP during water loading and a defect in the
regulatory function of AVP on c-AMP with a seconda-
rily up regulation of AQP2 water channels.
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